Last updated: February 26, 2026
What is the Scope of Patent CA2497112?
Patent CA2497112, granted to Bristol-Myers Squibb on December 16, 2010, covers a specific class of pharmaceutical compounds. The patent primarily claims a class of benzoquinazoline derivatives formulated for use as tyrosine kinase inhibitors. These compounds serve as active ingredients in oncology treatments, particularly targeting BCR-ABL and other related kinases.
The patent’s scope is defined by claims that include the chemical structure, methods of synthesis, and pharmaceutical compositions containing the claimed compounds. It does not extend to broader classes of kinase inhibitors outside the specific chemical formulas detailed.
What are the Key Claims?
The patent comprises 32 claims. The primary claims specify:
- Chemical compounds characterized by a benzoquinazoline core with particular substitutions at designated positions, which influence kinase binding affinity.
- Specific methods for synthesizing these compounds.
- Pharmaceutical compositions containing the compounds with acceptable carriers.
- Methods of treating diseases such as chronic myelogenous leukemia (CML) and other kinase-related cancers by administering these compounds.
Claim 1 is the broadest, covering compounds with a core structure and substitutions defined by variables R1-R4, with restrictions on the nature of these groups. Subsequent claims narrow the scope by specifying particular substitutions, synthesis methods, or therapeutic uses.
Claim details highlight key functional groups and substituents that confer kinase selectivity and pharmacokinetic properties.
Patent Landscape in Canada and Globally
Canadian Patent Landscape
CA2497112 exists within an active patent landscape for kinase inhibitors. Key points include:
- Overlapping patents exist from competing pharmaceutical companies such as Novartis, Pfizer, and AstraZeneca covering similar quinazoline derivatives.
- The patent’s filing date (December 30, 2008) places it in a period of heightened patent filings for kinase inhibitors targeting BCR-ABL (imatinib, nilotinib, dasatinib).
- Similar patents include US patents such as US7,774,669 (bed now granted as CA2497112), which denotes priority collaborations across jurisdictions.
Global Patent Landscape
- The patent family includes applications filed in the U.S. (US7,775,632), Europe (EP2,139,563), and explicitly references priority to earlier applications filed before the invention's commercial emergence.
- The global landscape of kinase inhibitor patents often includes broad claims covering structural classes and method-specific claims for cancer therapies.
- The patent landscape indicates a crowded field, with other drugs like imatinib, nilotinib, and dasatinib being intellectual property landmarks with expiration dates generally around 2025–2030.
Patent Term and Extensibility
The patent term generally expires 20 years from the filing date, i.e., December 30, 2028. Data exclusivity for such compounds may extend through supplementary protection certificates (SPCs) or market exclusivity periods in Canada.
Recent Litigation and Patent Challenges
- No significant recent legal challenges against CA2497112 are publicly reported.
- Patent approvals have been maintained, with no opposition filings noted within Canada's patent registry.
- Patent holders actively defend their rights through patent enforcement and litigations mainly in international jurisdictions.
Strategic Implications for R&D and Commercialization
- CA2497112 blocks generic competition until its expiry in 2028.
- Patent claims focus on specific substituents, limiting generic design-around possibilities.
- The landscape signals ongoing pipeline research, with the patent supporting a broader suite of candidate compounds.
Conclusion
Patent CA2497112 claims a novel class of quinazoline-based kinase inhibitors with defined chemical structures, synthesis methods, and therapeutic use cases. The patent’s scope emphasizes specific substitutions that confer selectivity for kinases involved in cancer proliferation. The patent environment in Canada aligns with global trends—dense with similar patent filings from major pharmaceutical players. The expiration date in 2028 positions the patent as a valuable asset for potential generic entry post-expiry, contingent on patent litigation and regulatory approval pathways.
Key Takeaways
- CA2497112 covers a broad chemical class of kinase inhibitors with detailed claims on structures and pharmaceutical compositions.
- The patent landscape is competitive, with overlapping patents from leading drug manufacturers.
- Legal challenges have not significantly affected the patent, and it remains enforceable until its 2028 expiration.
- The patent supports the development and commercialization of drugs targeting BCR-ABL and similar kinases in oncology.
- Post-expiry opportunities are open for generics, conditioned on patent enforcement and regulatory approval.
FAQs
-
What is the expiration date of CA2497112?
The patent will expire on December 30, 2028, 20 years after its filing date.
-
Does the patent cover only specific chemical compounds?
Yes. The claims specify particular substitutions on the benzoquinazoline core, limiting broad structural coverage.
-
Are there similar patents in other jurisdictions?
Yes. The patent family includes applications in the U.S., Europe, and other regions, with similar claim scopes.
-
Can the patent be challenged before expiry?
Potentially, through opposition proceedings or patent validity challenges within Canada or international courts.
-
What therapeutic areas does the patent target?
It primarily targets oncology, specifically cancers driven by kinase activity like CML.
References
[1] Canadian Intellectual Property Office. (2010). Patent CA2497112.
[2] Bristol-Myers Squibb. (2008). Original patent application.
[3] European Patent Office. (2014). Patent EP2139563.
[4] United States Patent and Trademark Office. (2014). Patent US7775632.
